Synthetic lethality is defined as a type of genetic interaction where the combination of two genetic events results in cell death, whereas each of them separately does not. Synthetic lethality can be a useful tool in personalised oncology. MLH1 is a cancer-related gene that has a central role in DNA mismatch-repair and TP53 is the most frequently mutated gene in cancer. To identify genetic events that can lead to tumour death once either MLH1 or TP53 is mutated, a genome-wide genetic screening was performed. Thus, mutations in all protein-coding genes were introduced into haploid human embryonic stem cells (hESCs) with and without loss-of-function mutations in the MLH1 or TP53 genes. These experiments uncovered a list of putative hits with EXO1, NR5A2, and PLK2 genes for MLH1, and MYH10 gene for TP53 emerging as the most promising candidates. Synthetic lethal interactions of these genes were validated genetically or chemically using small molecules that inhibit these genes. The specific effects of SR1848, which inhibits NR5A2, ON1231320 or BI2536, which inhibits PLK2, and blebbistatin, which inhibits MYH10, were further validated in cancer cell lines. Finally, animal studies with CCL xenografts showed the selective effect of the small molecule BI2536 on MLH1-null tumours and of blebbistatin on TP53-mutated tumours. Thus, demonstrating their potential for personalised medicine, and the robustness of genetic screening in haploid hESCs in the context of cancer therapeutics.
| [1] |
A. Huang, L. A. Garraway, A. Ashworth, and B. Weber, “Synthetic Lethality as an Engine for Cancer Drug Target Discovery,” Nature Reviews Drug Discovery 19 (2020): 23–38.
|
| [2] |
W. G. Kaelin, “The Concept of Synthetic Lethality in the Context of Anticancer Therapy,” Nature Reviews. Cancer 5 (2005): 689–698.
|
| [3] |
A. Mullard, “Synthetic Lethality Screens Point the Way to New Cancer Drug Targets,” Nature Reviews. Drug Discovery 16 (2017): 736.
|
| [4] |
A. Mullard, “DNA Damage Response Drugs for Cancer Yield Continued Synthetic Lethality Learnings,” Nature Reviews. Drug Discovery 21 (2022): 403–405.
|
| [5] |
S. Parameswaran, D. Kundapur, F. S. Vizeacoumar, A. Freywald, M. Uppalapati, and F. J. Vizeacoumar, “A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality,” Trends Cancer 5 (2019): 11–29.
|
| [6] |
C. J. Lord and A. Ashworth, “PARP Inhibitors: Synthetic Lethality in the Clinic,” Science 355 (2017): 1152–1158.
|
| [7] |
B. De Kegel, N. Quinn, N. A. Thompson, D. J. Adams, and C. J. Ryan, “Comprehensive Prediction of Robust Synthetic Lethality Between Paralog Pairs in Cancer Cell Lines,” Cell Systems 12 (2021): 1144–1159 e1146.
|
| [8] |
B. Zhang, C. Tang, Y. Yao, et al., “The Tumor Therapy Landscape of Synthetic Lethality,” Nature Communications 12 (2021): 1275.
|
| [9] |
V. A. Blomen, P. Májek, L. T. Jae, et al., “Gene Essentiality and Synthetic Lethality in Haploid Human Cells,” Science 350 (2015): 1092–1096.
|
| [10] |
A. Yilmaz, C. Braverman-Gross, A. Bialer-Tsypin, M. Peretz, and N. Benvenisty, “Mapping Gene Circuits Essential for Germ Layer Differentiation via Loss-Of-Function Screens in Haploid Human Embryonic Stem Cells,” Cell Stem Cell 27 (2020): 679–691.
|
| [11] |
A. Yilmaz, M. Peretz, A. Aharony, I. Sagi, and N. Benvenisty, “Defining Essential Genes for Human Pluripotent Stem Cells by CRISPR-Cas9 Screening in Haploid Cells,” Nature Cell Biology 20 (2018): 610–619.
|
| [12] |
L. Castells-Roca, E. Tejero, B. Rodríguez-Santiago, and J. Surrallés, “CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer,” Cancers 13 (2021): 1591.
|
| [13] |
A. Yilmaz, M. Peretz, I. Sagi, and N. Benvenisty, “Haploid Human Embryonic Stem Cells: Half the Genome, Double the Value,” Cell Stem Cell 19 (2016): 569–572.
|
| [14] |
J. W. Hickmott, “Origin of MLH1, MSH2, MSH6 and PMS2 Mutations Can Help Inform Long-Term Care Strategies for Patients With Colorectal and Endometrial Cancer,” Clinical Genetics 87 (2015): 534–535.
|
| [15] |
M. P. Hitchins, V. A. Lin, A. Buckle, et al., “Epigenetic Inactivation of a Cluster of Genes Flanking MLH1 in Microsatellite-Unstable Colorectal Cancer,” Cancer Research 67 (2007): 9107–9116.
|
| [16] |
I. Marcos, S. Borrego, M. Urioste, C. García-Vallés, and G. Antiñolo, “Mutations in the DNA Mismatch Repair Gene MLH1 Associated With Early-Onset Colon Cancer,” Journal of Pediatrics 148 (2006): 837–839.
|
| [17] |
T. M. Kim, P. W. Laird, and P. J. Park, “The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes,” Cell 155 (2013): 858–868.
|
| [18] |
T. M. Kim and P. J. Park, “A Genome-Wide View of Microsatellite Instability: Old Stories of Cancer Mutations Revisited With New Sequencing Technologies,” Cancer Research 74 (2014): 6377–6382.
|
| [19] |
N. Pecina-Slaus, A. Kafka, I. Salamon, and A. Bukovac, “Mismatch Repair Pathway, Genome Stability and Cancer,” Frontiers in Molecular Biosciences 7 (2020): 122.
|
| [20] |
T. Buchler, “Microsatellite Instability and Metastatic Colorectal Cancer - A Clinical Perspective,” Frontiers in Oncology 12 (2022): 888181.
|
| [21] |
F. Bianchi, M. Raponi, F. Piva, et al., “An Intronic Mutation in MLH1 Associated With Familial Colon and Breast Cancer,” Familial Cancer 10 (2011): 27–35.
|
| [22] |
H. Fredriksson, T. Ikonen, V. Autio, et al., “Identification of Germline MLH1 Alterations in Familial Prostate Cancer,” European Journal of Cancer 42 (2006): 2802–2806.
|
| [23] |
S. S. Malik, A. Zia, S. Mubarik, et al., “Correlation of MLH1 Polymorphisms, Survival Statistics, In Silico Assessment and Gene Downregulation With Clinical Outcomes Among Breast Cancer Cases,” Molecular Biology Reports 47 (2020): 683–692.
|
| [24] |
S. Nourmohammadi Abadchi, L. A. Sena, E. S. Antonarakis, et al., “MLH1 Loss in Primary Prostate Cancer,” JCO Precision Oncology 7 (2023): e2200611.
|
| [25] |
F. Sanguedolce, A. Cormio, P. Massenio, et al., “Altered Expression of HER-2 and the Mismatch Repair Genes MLH1 and MSH2 Predicts the Outcome of T1 High-Grade Bladder Cancer,” Journal of Cancer Research and Clinical Oncology 144 (2018): 637–644.
|
| [26] |
P. A. Muller and K. H. Vousden, “Mutant p53 in Cancer: New Functions and Therapeutic Opportunities,” Cancer Cell 25 (2014): 304–317.
|
| [27] |
T. Soussi and K. G. Wiman, “Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm,” Cancer Cell 12 (2007): 303–312.
|
| [28] |
S. Banin, L. Moyal, S. Y. Shieh, et al., “Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage,” Science 281 (1998): 1674–1677.
|
| [29] |
H. S. Goh, J. Yao, and D. R. Smith, “p53 Point Mutation and Survival in Colorectal Cancer Patients,” Cancer Research 55 (1995): 5217–5221.
|
| [30] |
R. Okubo, H. Masuda, and N. Nemoto, “p53 Mutation Found to Be a Significant Prognostic Indicator in Distal Colorectal Cancer,” Oncology Reports 8 (2001): 509–514.
|
| [31] |
A. Russo, V. Bazan, B. Iacopetta, D. Kerr, T. Soussi, and N. Gebbia, “The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of Mutation, and Adjuvant Treatment,” Journal of Clinical Oncology 23 (2005): 7518–7528.
|
| [32] |
J. G. Doench, N. Fusi, M. Sullender, et al., “Optimized sgRNA Design to Maximize Activity and Minimize Off-Target Effects of CRISPR-Cas9,” Nature Biotechnology 34 (2016): 184–191.
|
| [33] |
E. M. Chan, T. Shibue, J. M. McFarland, et al., “WRN Helicase Is a Synthetic Lethal Target in Microsatellite Unstable Cancers,” Nature 568 (2019): 551–556.
|
| [34] |
S. A. Martin, M. Hewish, D. Sims, C. J. Lord, and A. Ashworth, “Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair–Deficient Cancers,” Cancer Research 71 (2011): 1836–1848.
|
| [35] |
S. A. Martin, N. McCabe, M. Mullarkey, et al., “DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1,” Cancer Cell 17 (2010): 235–248.
|
| [36] |
K. Madden-Hennessey, D. Gupta, A. A. Radecki, C. Guild, A. Rath, and C. D. Heinen, “Loss of Mismatch Repair Promotes a Direct Selective Advantage in Human Stem Cells,” Stem Cell Reports 17 (2022): 2661–2673.
|
| [37] |
Y. Avior, I. Sagi, and N. Benvenisty, “Pluripotent Stem Cells in Disease Modelling and Drug Discovery,” Nature Reviews. Molecular Cell Biology 17 (2016): 170–182.
|
| [38] |
Y. Avior, E. Lezmi, D. Yanuka, and N. Benvenisty, “Modeling Developmental and Tumorigenic Aspects of Trilateral Retinoblastoma via Human Embryonic Stem Cells,” Stem Cell Reports 8 (2017): 1354–1365.
|
| [39] |
D. F. Lee, J. Su, H. S. Kim, et al., “Modeling Familial Cancer With Induced Pluripotent Stem Cells,” Cell 161 (2015): 240–254.
|
| [40] |
A. Rath, A. Mishra, V. D. Ferreira, et al., “Functional Interrogation of Lynch Syndrome-Associated MSH2 Missense Variants via CRISPR-Cas9 Gene Editing in Human Embryonic Stem Cells,” Human Mutation 40 (2019): 2044–2056.
|
| [41] |
J. P. Gillet, S. Varma, and M. M. Gottesman, “The Clinical Relevance of Cancer Cell Lines,” Journal of the National Cancer Institute 105 (2013): 452–458.
|
| [42] |
J. L. Wilding and W. F. Bodmer, “Cancer Cell Lines for Drug Discovery and Development,” Cancer Research 74 (2014): 2377–2384.
|
| [43] |
M. Ozery-Flato, C. Linhart, L. Trakhtenbrot, S. Izraeli, and R. Shamir, “Large-Scale Analysis of Chromosomal Aberrations in Cancer Karyotypes Reveals Two Distinct Paths to Aneuploidy,” Genome Biology 12 (2011): R61.
|
| [44] |
E. M. Chan, K. J. Foster, and A. J. Bass, “WRN Is a Promising Synthetic Lethal Target for Cancers With Microsatellite Instability (MSI),” Cancer Treatment and Research 186 (2023): 313–328.
|
| [45] |
A. Ferreira, F. Pereira, C. Reis, M. J. Oliveira, M. J. Sousa, and A. Preto, “Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications,” Cells 11 (2022): 2183.
|
| [46] |
L. L. Fava, F. Schuler, V. Sladky, et al., “The PIDDosome Activates p53 in Response to Supernumerary Centrosomes,” Genes & Development 31 (2017): 34–45.
|
| [47] |
M. Steegmaier, M. Hoffmann, A. Baum, et al., “BI 2536, a Potent and Selective Inhibitor of Polo-Like Kinase 1, Inhibits Tumor Growth In Vivo,” Current Biology 17 (2007): 316–322.
|
| [48] |
S. M. Corsello, R. T. Nagari, R. D. Spangler, et al., “Discovering the Anti-Cancer Potential of Non-oncology Drugs by Systematic Viability Profiling,” Nature Cancer 1 (2020): 235–248.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.
PDF
